Cell Therapies Supplier Market Overview

  • The supplier market is fragmented and developing. Academic institutions are the major supply base for this market due to the access to skilled labor and government funded research programs.
  • 70 percent of the clinical trials were sponsored by the academic institutions (with public funds) and 30 percent by CROs for cell therapy in 2015 
  • The US and Canada are the leading markets for cell therapy and most of the suppliers, CROs, as well as academia are populated in this region. Europe is the second leading market with several universities focusing on cell therapy 
  • Academia will continue to be the key supply base due to the complexity of trials, safety concerns and the relatively lower business risk inclination of CROs for cell therapy trials 
  • Preliminary results in Phase I and II of such trials, which have minor benefits in extensive Phase III research (due to population heterogeneity), and limited evidence of efficacy of these trials makes it a technically challenging service line


Technology Overview

Supply Chain Concerns 

  • For individual supply chains, the number of suppliers available are few 
  • To mitigate risk, companies prefer manufacturing these materials in-house at this stage

Open Innovation in Stem Cells 

The industry is practicing open innovation in this category 

  • Stem cells are available for development, to researchers, by Luna, California Institute for Regenerative Medicine and the European Biobank
  • Such banks are estimated to save up to six months and $50,000–100,000 per patient 
  • Cellsartis AB has been asked to share its cell lines 
  • Lonza has publicly released documents regarding its GMP approved stem cell manufacturing technology encouraging further innovation

Cell Therapies-Market Trends


  • T-cell research conducted by non-pharmaceutical organizations is more advanced than pharmaceutical organizations 
  • As T-ell therapies are receiving priority reviews, outsourcing research activities to organizations focusing on different types of T-cell therapies can provide market advantages 
  • Open innovation in the stem cells industry is encouraging research in development of therapies and manufacturing practices 
  • This is a result of allowing public use of private cell banks and advanced manufacturing practices
  • As standardized manufacturing techniques are developed, the market is expected to expand


  • Stem cells can differentiate into more than 200 lines 
  • As manufacturing practices for stable cell lines have not been established, outsourcing manufacturing capabilities is a concern 
  • For autologous cell therapies, which are the most common therapies, involves cells from individual patients; the concept of commercial batch manufacturing is difficult to establish 
  • This will also involve location constraints 
  • Existing centrifugal and filtration techniques are not feasible to harvest and recover live cells 
  • The supply chains established by non-pharmaceutical organizations have high levels of risk 
  • As a lot of small suppliers own the IP for various technologies contributing to the supply chain, organizations are forced to rely heavily on these suppliers for their internal processes leaving their supply chains vulnerable to risk